Rosetta Genomics to Host Business Update Conference Call on April 1, 2014

Rosetta Genomics to Host Business Update Conference Call on April 1, 2014 
2013 Annual Report on Form 20-F to Be Filed With SEC 
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 03/25/14 -- 
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics and therapeutics,
today announced that following the close of the U.S. stock market on
Monday, March 31, 2014, the Company will file its Annual Report on
Form 20-F for the year ended December 31, 2013 with the U.S.
Securities and Exchange Commission ("SEC"). The Form 20-F will
include audited annual consolidated financial statements, as well as
additional information regarding the Company. The Form 20-F will be
available at and at  
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta
Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta
Genomics, will host a conference call on Tuesday, April 1, 2014 at
10:00 a.m. Eastern time (7:00 a.m. Pacific time) to provide an update
on the Company's business and respond to questions. 
Individuals interested in listening to the conference call may do so
by dialing (866) 239-5859, or for international callers (702)
495-1913. The conference ID number is 19429704. The call is also
being webcast, and can be accessed on the investor relations section
of the Company's Web site at and also at  
A telephone replay will be available through April 8, 2014 by dialing
(855) 859-2056 or for international callers (404) 537-3406, and
entering the Conference ID number 19429704. The webcast will be
available for 30 days following the completion of the call.  
About Rosetta Cancer Testing Services 
 Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). The Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data;
it is the treating physician's responsibility to diagnose and
administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the
Rosetta Cancer Origin Test(TM), 60,000 from the Rosetta Mesothelioma
Test(TM), 65,000 from the Rosetta Kidney Cancer Test(TM) and 226,000
patients from the Rosetta Lung Cancer Test(TM). The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. For more information, please visit Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000. 
About Rosetta Genomics
 Founded in 2000, Rosetta's integrative
research platform combining bioinformatics and state-of-the-art
laboratory processes has led to the discovery of hundreds of
biologically validated novel human microRNAs. Building on its strong
patent position and proprietary platform technologies, Rosetta is
working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic
tools and therapeutics. Rosetta currently commercializes a full range
of microRNA-based molecular diagnostics. Rosetta's cancer testing
services are commercially available through its Philadelphia-based
CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized
Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award. For more
information, please visit 
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta filing its year-end
statements on March 31, 2014, constitute forward-looking statements
for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks more
fully discussed in the "Risk Factors" section of Rosetta's Annual
Report on Form 20-F for the year ended December 31, 2012 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be
relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any forward-looking
statements unless required by law. 
Company Contact: 
Rosetta Genomics 
Ken Berlin
President & CEO 
(609) 419-9003 
Investor Contacts: 
Anne Marie Fields
(212) 838-3777
Bruce Voss
(310) 691-7100 
Press spacebar to pause and continue. Press esc to stop.